A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

M. Apovian, Caroline; J. Aronne, Louis; Rubino, Domenica; D. Still, Christopher; R. Wyatt, Holly; Burns, Colleen; Kim, Dennis; Dunayevich, Eduardo; the COR‐II Study Group, for

doi:10.1002/oby.20309

Public

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Published in Obesity • Feb 14, 2013

Authors:

Caroline M. Apovian

Louis J. Aronne

Domenica Rubino

Abstract

OBJECTIVE: To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants. DESIGN AND METHODS: CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ...

Subject

Medicine

Placebo

Weight loss

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!